KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Current Leases: 2020-2025

Historic Current Leases for Aurinia Pharmaceuticals (AUPH) over the last 5 years, with Sep 2025 value amounting to $16.3 million.

  • Aurinia Pharmaceuticals' Current Leases rose 9.26% to $16.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.3 million, marking a year-over-year increase of 9.26%. This contributed to the annual value of $14.0 million for FY2024, which is 3.85% down from last year.
  • As of Q3 2025, Aurinia Pharmaceuticals' Current Leases stood at $16.3 million, which was up 0.88% from $16.2 million recorded in Q2 2025.
  • In the past 5 years, Aurinia Pharmaceuticals' Current Leases registered a high of $16.3 million during Q3 2025, and its lowest value of $918,000 during Q3 2022.
  • Its 3-year average for Current Leases is $13.3 million, with a median of $14.0 million in 2024.
  • Its Current Leases has fluctuated over the past 5 years, first dropped by 17.37% in 2022, then skyrocketed by 1,460.79% in 2023.
  • Over the past 5 years, Aurinia Pharmaceuticals' Current Leases (Quarterly) stood at $1.1 million in 2021, then fell by 11.61% to $936,000 in 2022, then spiked by 1,460.79% to $14.6 million in 2023, then declined by 3.85% to $14.0 million in 2024, then climbed by 9.26% to $16.3 million in 2025.
  • Its last three reported values are $16.3 million in Q3 2025, $16.2 million for Q2 2025, and $14.5 million during Q1 2025.